Autoimmune disease therapy - Hadassah Medical Organization/Harvard Medical School

Drug Profile

Autoimmune disease therapy - Hadassah Medical Organization/Harvard Medical School

Alternative Names: Anti-CD3+glycolipid

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hadassah Medical Organization; Harvard Medical School
  • Class Glycolipids; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders in Israel (PO)
  • 26 Apr 2009 Pharmacodynamics data from a preclinical trial in Hepatitis presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
  • 31 Jan 2008 Phase-I clinical trials in Autoimmune disorders in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top